IRLAB Therapeutics Q2: Focus on value creation following strengthened financials - Redeye

Redeye provides a research update following IRLAB's Q2 report. We note that capital allocation and operational efficiency following the recent rights issue will be important to realize the company's pipeline value.

Länk till analysen i sin helhet: https://www.redeye.se/research/1126091/irlab-therapeutics-q2-focus-on-value-creation-following-strengthened-financials?utm_source=finwire&utm_medium=RSS